MarketCap
Facebook
X
TelegramQuarterly report 2024-Q3
added 05-30-2026
Lumos Pharma Shares 2011-2026 | LUMO
Annual Shares Lumos Pharma
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8.15 M | 8.37 M | 8.33 M | 6.78 M | 1.3 M | 37.2 M | 31.3 M | 29 M | 28.6 M | 27.8 M | 25.3 M | 20.8 M | 6.06 M | 3.35 M | 3.16 M | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 37.2 M | 1.3 M | 16.4 M |
Quarterly Shares Lumos Pharma
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8.33 M | 8.11 M | 8.1 M | 8.1 M | 7.98 M | 8.16 M | 8.24 M | 8.27 M | 8.39 M | 8.37 M | 8.36 M | 8.36 M | 8.36 M | 8.73 M | 8.32 M | 8.31 M | 8.29 M | 8.29 M | 2.19 M | 1.18 M | 37.3 M | 37.3 M | 37.3 M | 37.3 M | 37.2 M | 37.2 M | 37.2 M | 37.1 M | 29.9 M | 29.2 M | 29.2 M | 29.2 M | 29 M | 28.9 M | 28.9 M | 28.8 M | 28.7 M | 28.7 M | 28.2 M | 28 M | 27.9 M | 27.9 M | 27.6 M | 26.6 M | 25.7 M | 25.6 M | 23.9 M | 21 M | 20.9 M | 20.7 M | 20.6 M | 20.6 M | 3.66 M | 3.65 M | 3.64 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 37.3 M | 1.18 M | 19.9 M |
Shares of other stocks in the Biotechnology industry
| Issuer | Shares | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
38.7 M | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MorphoSys AG
MOR
|
33.4 M | - | 2.43 % | $ 254 M |  Germany |
 |
Happiness Biotech Group Limited
HAPP
|
4.73 M | - | 1.35 % | $ 17.8 M |  China |
 |
Coherus BioSciences
CHRS
|
117 M | $ 1.45 | -7.94 % | $ 170 M |  USA |
 |
AgeX Therapeutics
AGE
|
10.2 M | - | -10.17 % | $ 12.2 K | USA |
 |
I-Mab
IMAB
|
220 M | - | - | $ 866 M | China |
 |
Deciphera Pharmaceuticals
DCPH
|
85.1 M | - | - | $ 2.18 B | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
219 M | - | - | $ 40.3 B | USA |
 |
Compugen Ltd.
CGEN
|
93.4 M | $ 2.1 | -5.41 % | $ 196 M |  Israel |
 |
Genfit SA
GNFT
|
44.7 B | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
543 M | - | -13.47 % | $ 169 M | France |
 |
Alpine Immune Sciences
ALPN
|
50 M | - | - | $ 2.17 B | USA |
 |
ASLAN Pharmaceuticals Limited
ASLN
|
192 M | - | -14.27 % | $ 1.7 M |  Singapore |
 |
AstraZeneca PLC
AZN
|
1.55 B | - | - | $ 96.9 B |  Britain |
 |
BioNTech SE
BNTX
|
242 M | $ 88.08 | -1.69 % | $ 21.3 B | Germany |
 |
CureVac N.V.
CVAC
|
224 M | - | - | $ 867 M | Germany |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
4.58 M | - | -1.52 % | $ 24.7 M | USA |
 |
Athira Pharma
ATHA
|
4.28 M | - | - | $ 269 M | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
9.34 B | - | 0.74 % | $ 768 M | Israel |
 |
Abcam plc
ABCM
|
229 M | - | - | $ 4.9 B | Britain |
 |
Galera Therapeutics
GRTX
|
98.5 M | - | -32.59 % | $ 7.61 M | USA |
 |
Midatech Pharma plc
MTP
|
54.9 B | - | -18.52 % | $ 27.3 M | Britain |
 |
CRISPR Therapeutics AG
CRSP
|
89.9 M | $ 51.84 | -8.97 % | $ 4.66 B |  Schweiz |
 |
Affimed N.V.
AFMD
|
120 M | - | -34.95 % | $ 21.5 M | Germany |
 |
Институт стволовых клеток человека
ISKJ
|
75 M | - | - | - |  Russia |
 |
Checkmate Pharmaceuticals
CMPI
|
21.6 M | - | - | $ 231 M | USA |
 |
Celyad Oncology SA
CYAD
|
22.6 M | - | - | $ 12.5 M |  Belgium |
 |
Berkeley Lights
BLI
|
68.9 M | - | -7.31 % | $ 87 M | USA |
 |
Celldex Therapeutics
CLDX
|
66.4 M | $ 28.62 | -4.38 % | $ 1.9 B | USA |
 |
Generation Bio Co.
GBIO
|
66.6 M | - | - | $ 344 M | USA |
 |
IMV
IMV
|
8.34 M | - | - | $ 13.1 M | Canada |
 |
Akero Therapeutics
AKRO
|
67.1 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
34.4 M | - | 0.23 % | $ 488 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
15.4 M | - | - | $ 7.46 M | Israel |
 |
Cyclacel Pharmaceuticals
CYCCP
|
2.19 M | - | -4.36 % | $ 27 M | USA |
 |
Freeline Therapeutics Holdings plc
FRLN
|
59.3 M | - | - | $ 384 M | Britain |
 |
Gracell Biotechnologies
GRCL
|
338 M | - | - | $ 3.37 B | China |
 |
Anika Therapeutics
ANIK
|
14.3 M | $ 14.48 | -2.1 % | $ 208 M | USA |
 |
Advaxis
ADXS
|
6.02 M | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
3.17 M | - | 5.93 % | $ 314 M | Canada |
 |
Aeglea BioTherapeutics
AGLE
|
78.2 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
45 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
14.3 M | - | 1.93 % | $ 17.4 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
1.65 M | $ 3.09 | -2.22 % | $ 5.09 M | Israel |
 |
Aptose Biosciences
APTO
|
2.45 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
67.7 M | - | -39.0 % | $ 4.57 M | USA |
 |
Albireo Pharma
ALBO
|
19.2 M | - | -0.23 % | $ 916 M | USA |
 |
AlloVir
ALVR
|
15.3 M | - | 4.14 % | $ 49.1 M | USA |
 |
Allakos
ALLK
|
88.8 M | - | - | $ 28.6 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
127 M | $ 21.23 | -3.28 % | $ 2.7 B | USA |